Philip Wenk
For Philip Wenk, appreciation for the mission of St. Jude Children’s Research Hospital began 45 years ago when he was a student at the University of Tennessee College of Dentistry.
St. Jude had recently announced a dramatic increase in childhood leukemia survival rates and a major hospital expansion was underway.
“It really had that startup feel,” Wenk recalls.
Now, as president and CEO of Delta Dental of Tennessee, Wenk marvels at what generous people across the nation have helped build.
“I tell my friends, ‘You need to tour St. Jude,’” Wenk says. “When I walk through St. Jude, I get that tingle in my back, because you know you are in the presence of greatness.”
Delta Dental and the company’s Smile180 Foundation have provided about $2 million in support of treatment, research and awareness:
- Support for the hospital’s onsite dental clinic, including a renovation, helps St. Jude control and minimize patients’ dental problems.
- A $1 million gift for the St. Jude Graduate School of Biomedical Sciences helps ensure the training of tomorrow’s scientists.
- Sponsorship of several St. Jude events, including benefit concerts This Show Saves Lives and the St. Jude Jam, raises funds and awareness for the hospital.
Because Delta Dental and Smile180 have helped increase access to dental care in underserved communities, Wenk identifies closely with the hospital’s commitment to freely share its research.
“It sends the message to the world: Don’t hide your light under a basket,” Wenk says. “When people think about giving to St. Jude, I hope they think about everything St. Jude is giving to the world.”
Wenk’s son survived non-Hodgkin lymphoma as a young man. Having seen firsthand how those medical bills added up, Wenk says it means the world that families never receive a bill from St. Jude.
“I know these parents are so scared of their child dying,” Wenk says. “To know there is no cost for treatment has a huge effect on their psyche. Instead of worrying about finances, they can focus on helping their child heal.”
More articles from this issue
-
A Cancer Chameleon: Mixed-phenotype Acute Leukemia
Features of mixed-phenotype acute leukemia can change, enough to switch the diagnosis from one acute leukemia to the other.
-
Science Alliance: Fighting PKAN Together
Married St. Jude researchers broaden their collaboration to develop a novel medication for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder.
-
St. Jude and WHO Unite to Save Lives
The greatest predictor of survival for a child with cancer is where that child happens to live. St. Jude and World Health Organization join forces to change that sobering fact.
-
Flu Fighters: How the Immune System Protects Infants from Influenza
St. Jude investigators discover how guardian T cells help combat influenza in infants and young children.
-
Dance of the T Cells
A new therapy at St. Jude called CAR T-cell therapy holds hope for many children who have cancer that returns or is hard to treat.
-
Dawn of a New Era for Aggressive Brain Tumors
Relapsed brain tumors have been difficult to treat, but a new approach at St. Jude offers a ray of hope.
-
Cryo-EM: It’s a Small, Small World
Scientists in the new St. Jude Cryo-EM and Tomography Center zoom in on staggeringly small structures to better understand biological systems.
-
Touchdown, St. Jude
Football stars from Lausanne Collegiate School turn fundraising champs for the hospital by winning the 2018 Touchdowns Against Cancer national championship.
-
Run for a Reason
More than 26,000 runners and walkers recently laced up their shoes for the 2018 St. Jude Memphis Marathon Weekend, the largest single-day fundraising event for St. Jude.
-
Research Highlights - Winter 2019
Learn about whole genome sequencing; the Hippo pathway; scavenger immune cells; tumor suppressor gene SPOP; free acute leukemia models; and more.